secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023510
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30
--------------------------------------------------------------------------------

- Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.
- BREXAFEMME net revenue $1.6M (up 23% QoQ); 5,785 total prescriptions written, up 13% vs Q2.
- Cash, equivalents and short-term investments $96.1M; projected runway into Q2 2024.
- CEO Marco Taglietti to retire Dec 31, 2022; David Angulo (CMO) to become CEO effective Jan 1, 2023.
- PDUFA date Nov 30, 2022 for BREXAFEMME sNDA for prevention of recurrent VVC; company seeking commercialization partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/0000950170-22-023510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/scyx-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer